Development of a polymeric matrix metalloproteinase inhibitor as a bioactive stent coating material for prevention of restenosis

Journal of Biomedical Materials Research - Part B Applied Biomaterials

Volumn 80, Issue 1, 2007, Pages 260-267

  Nakayama, Yasuhide ^a,b   Masuda, Takeshi ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Cell proliferation inhibition; MMP inhibitor; Polymeric MMPI; Prevention of restenosis; Stent

Indexed keywords

CELL PROLIFERATION INHIBITION; MMP INHIBITORS; POLYMERIC MMPI; RESTENOSIS; STENTS;

ADHESION; BIOCOMPATIBILITY; CELLS; DRUG PRODUCTS; HYDROPHOBICITY;

ENZYME INHIBITION;

BIOMATERIAL; CARBONYL DERIVATIVE; CARBOXYL GROUP; HYDROXY 5 CARBOXYETHYLCARBONYLOXY 2 METHYL 4 (4 PHENOXYBENZOYL)AMINOPENTANAMIDE; MATRIX METALLOPROTEINASE INHIBITOR; METHACRYLIC ACID BUTYL ESTER; METHACRYLIC ACID DERIVATIVE; MONOMER; POLYMER; UNCLASSIFIED DRUG; VINYL DERIVATIVE;

ARTICLE; CELL ADHESION; CELL DAMAGE; CELL PROLIFERATION; CHEMICAL COMPOSITION; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG ELUTING STENT; MATERIAL COATING; MOLECULAR WEIGHT; PHYSICAL CHEMISTRY; POLYMERIZATION; RESTENOSIS; SMOOTH MUSCLE FIBER; STENT;

ANIMALS; BENZAMIDES; CATTLE; CELL CULTURE TECHNIQUES; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; COATED MATERIALS, BIOCOMPATIBLE; CORONARY RESTENOSIS; HUMANS; HYDROXAMIC ACIDS; MATERIALS TESTING; MATRIX METALLOPROTEINASES; MUSCLE, SMOOTH, VASCULAR; PROTEASE INHIBITORS; STENTS;

EID: 33845945975     PISSN: 00219304     EISSN: 15524981     Source Type: Journal    
DOI: 10.1002/jbm.b.30592     Document Type: Article

References (33)

1. Fattori R, Piva T. Drug-eluting stents in vascular intervention. Lancet 2003;361:247-249.
2. Iofina E, Haager PK, Radke PW, Langenberg R, Blindt R, Ortlepp J, Kuhl H, Hanrath P, Hoffmann R. Sirolimus- and paclitaxel-eluting stents in comparison with balloon angioplasty for treatment of in-stent restenosis. Catheter Cardiovasc Interv 2005;64:28-34.
3. Colombo A, Moses JW, Morice MC, Ludwig J, Holmes DR Jr, Spanos V, Louvard Y, Desmedt B, Di Mario C, Leon MB. Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation 2004;109:1244-1249.
4. Sousa JE, Costa MA, Abizaid A, Abizaid AS, Feres F, Pinto IM, Seixas AC, Staico R, Mattos LA, Sousa AG, Falotico R, Jaeger J, Popma JJ, Serruys PW. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: A quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 2001;103:192-195.
5. Tanabe K, Serruys PW, Grube E, Smits PC, Selbach G, van der Giessen WJ, Staberock M, de Feyter P, Muller R, Regar E, Degertekin N, Lighart JMR, Disco C, Backx B, Russell ME. TAXUS III trial. In-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation 2003;107:559-564.
6. Grube E, Buellesfeld L. Paclitaxel-eluting stents: Current clinical experience. Am J Cardiovasc Drugs 2004;4:355-360.
7. Nakayama Y, Ji-Youn K, Nishi S, Ueno H, Matsuda T. Development of high-performance stent: Gelatinous photogel-coated stent that permits drug delivery and gene transfer. J Biomed Mater Res 2001;57:559-566.
8. Nakayama Y, Nishi S, Ishibashi-Ueda H. Fabrication of drug-eluting covered stents with micropores and differential coating of heparin and FK506. Cardiovasc Radiat Med 2003;4:77-82.
9. Sheppard R, Eisenberg MJ, Donath D, Meerkin D. Intracoronary brachytherapy for the prevention of restenosis after percutaneous coronary revascularization. Am Heart J 2003;146:775-786.
10. Sidawy AN, Weiswasser JM, Waksman R. Peripheral vascular brachytherapy. J Vasc Surg 2002;35:1041-1047.
11. Rogers CD. Optimal stent design for drug delivery. Rev Cardiovasc Med 2004;5 (Suppl 2): S9-S15.
12. Ranade SV, Miller KM, Richard RE, Chan AK, Allen MJ, Helmus MN. Physical characterization of controlled release of paclitaxel from the TAXUS Express2 drug-eluting stent. J Biomed Mater Res A 2004;71:625-634.
13. Virmani R, Farb A, Guagliumi G, Kolodgie FD. Drug-eluting stents: Caution and concerns for long-term outcome. Coron Artery Dis 2004;15:313-318.
14. Kipshidze N, Leon MB, Tsapenko M, Falotico R, Kopia GA, Moses J. Update on sirolimus drug-eluting stents. Curr Pharm Des 2004;10:337-348.
15. Murphy JG, Schwartz RS, Edwards WD, Camrud AR, Vlietstra RE, Holmes DR Jr. Percutaneous polymeric stents in porcine coronary arteries. Initial experience with polyethylene terephthalate stents. Circulation 1992;86:1596-1604.
16. Holmes DR, Camrud AR, Jorgenson MA, Edwards WD, Schwartz RS. Polymeric stenting in the porcine coronary artery model: Differential outcome of exogenous fibrin sleeves versus polyurethane-coated stents. J Am Coll Cardiol 1994;24:525-531.
17. Massova I, Kotra LP, Fridman R, Mobashery S. Matrix metaloproteinases: Structures, evolution, and diversification. FASEB J 1998;12:1075-1095.
18. Nagase H. Activation mechanisms of matrix metalloproteinases. Biol Chem 1997;378:151-160.
19. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, Seiki M. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994;370:61-65.
20. Galis ZS, Muszynski M, Sukhova GK, Simon-Morrissey E, Unemori EN, Lark MW, Amento E, Libby P. Cytokine-stimulated human vascular smooth muscle cells synthesized a complement of enzymes required for extracellular matrix digestion. Circ Res 1994;75:181-189.
21. Baker AH, Zaltsman AB, George SJ, Newby AC. Divergent effects of tissue inhibitor of metalloproteinase-1, -2 or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vivo. J Clin Invest 1998;101:1478-1487.
22. Dollery CM, McEwan JR, Henney AM. Matrix metalloproteinases and cardiovasucular disease. Circ Res 1995;77:863-868.
23. Hidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 2001;93:178-193.
24. Supuran CT, Scozzafava A. Matrix metalloproteinases (MMPs) in proteinase and peptidase inhibition. In: Smith HJ, Simons C, editors. Recent Potential Targets for Drug Development. London: Taylor & Francis; 2002. pp 35-61.
25. Whittaker M, Floyd CD, Brown P, Gearing AJ. Design and therapeutic application of matrix metalloproteinase inhibitors. Chem Rev 1999;99:2735-2776.
26. Jia MC, Schwartz MA, Sang QA. Suppression of human microvascular endothelial cell invasion and morphogenesis with synthetic matrixin inhibitors. Targeting angiogenesis with MMP inhibitors. Adv Exp Med Biol 2000;476:181-194.
27. Yamada A, Uegaki A, Nakamura T, Ogawa K. ONO-4817, an orally active matrix metalloproteinase inhibitor, prevents lipopolysaccharide-induced proteoglycan release from the joint cartilage in guinea pigs. Inflamm Res 2000;49:144-146.
28. Mori T, Yamasaki S, Masui F, Matsuda M, Sasabe H, Zhou YF. Suppression of the development of experimentally induced uterine adenomyosis by a novel matrix metalloproteinase inhibitor, ONO-4817, in mice. Exp Biol Med 2001;226:429-433.
29. Masuda T, Nakayama Y. Development of a water-soluble matrix metalloproteinase inhibitor as an intra-arterial infusion drug for prevention of restenosis after angioplasty. J Med Chem 2003;46:3497-3501.
30. Nakayama Y, Miyamura M, Hirano Y, Goto K, Matsuda T. Preparation of poly(ethylene glycol)-polystyrene block copolymers using photochemistry of dithiocarbamate as a reduced cell-adhesive coating material. Biomaterials 1999;20:963-970.
31. Ito Y, Zheng J, Imanishi Y, Yonezawa K, Kasuga M. Protein-free cell culture on an arterial substrate with covalently immobilized insulin. Proc Natl Acad Sci USA 1996;93:3598-3601.
32. Nakayama Y, Nishi S, Ueda-Ishibashi H, Matsuda T. Fabrication of micropored elastomeric film-covered stents and acute-phase performances. J Biomed Mater Res A 2003;64:52-61.
33. Nishi S, Nakayama Y, Ishibashi-Ueda H, Matsuda T. Occlusion of experimental aneurysms with heparin-loaded, microporous stent grafts. Neurosurgery 2003;53:1397-1405.